WO1998041629A3 - Death domain containing receptor 5 - Google Patents

Death domain containing receptor 5 Download PDF

Info

Publication number
WO1998041629A3
WO1998041629A3 PCT/US1998/005377 US9805377W WO9841629A3 WO 1998041629 A3 WO1998041629 A3 WO 1998041629A3 US 9805377 W US9805377 W US 9805377W WO 9841629 A3 WO9841629 A3 WO 9841629A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain containing
death domain
containing receptor
proteins
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/005377
Other languages
French (fr)
Other versions
WO1998041629A2 (en
Inventor
Jian Ni
Reiner L Gentz
Guo-Liang Yu
Jeffrey Y Su
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26717514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998041629(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR10-1999-7008466A priority Critical patent/KR100527638B1/en
Priority to AU67635/98A priority patent/AU747635B2/en
Priority to NZ337795A priority patent/NZ337795A/en
Priority to DE69836956T priority patent/DE69836956T2/en
Priority to CA002285040A priority patent/CA2285040C/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to DK98912966T priority patent/DK0970213T3/en
Priority to JP54079098A priority patent/JP4330180B2/en
Priority to HK00104295.4A priority patent/HK1025352B/en
Priority to EP98912966A priority patent/EP0970213B1/en
Publication of WO1998041629A2 publication Critical patent/WO1998041629A2/en
Publication of WO1998041629A3 publication Critical patent/WO1998041629A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)

Abstract

The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
PCT/US1998/005377 1997-03-17 1998-03-17 Death domain containing receptor 5 Ceased WO1998041629A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP98912966A EP0970213B1 (en) 1997-03-17 1998-03-17 Death domain containing receptor 5
JP54079098A JP4330180B2 (en) 1997-03-17 1998-03-17 Death domain containing receptor 5
NZ337795A NZ337795A (en) 1997-03-17 1998-03-17 Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
DE69836956T DE69836956T2 (en) 1997-03-17 1998-03-17 RECEPTOR 5 CONTAINING A DOMAIN RESPONSIBLE FOR CELL DEATH
CA002285040A CA2285040C (en) 1997-03-17 1998-03-17 Death domain containing receptor 5
KR10-1999-7008466A KR100527638B1 (en) 1997-03-17 1998-03-17 Death domain containing receptor 5
DK98912966T DK0970213T3 (en) 1997-03-17 1998-03-17 Death domain-containing receptor
AU67635/98A AU747635B2 (en) 1997-03-17 1998-03-17 Death domain containing receptor 5
HK00104295.4A HK1025352B (en) 1997-03-17 1998-03-17 Death domain containing receptor 5

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4084697P 1997-03-17 1997-03-17
US60/040,846 1997-03-17
US5402197P 1997-07-29 1997-07-29
US60/054,021 1997-07-29

Publications (2)

Publication Number Publication Date
WO1998041629A2 WO1998041629A2 (en) 1998-09-24
WO1998041629A3 true WO1998041629A3 (en) 1998-10-29

Family

ID=26717514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005377 Ceased WO1998041629A2 (en) 1997-03-17 1998-03-17 Death domain containing receptor 5

Country Status (14)

Country Link
US (2) US7803615B1 (en)
EP (1) EP0970213B1 (en)
JP (2) JP4330180B2 (en)
KR (1) KR100527638B1 (en)
CN (2) CN1624128A (en)
AT (1) ATE352618T1 (en)
AU (1) AU747635B2 (en)
CA (2) CA2644454A1 (en)
DE (1) DE69836956T2 (en)
DK (1) DK0970213T3 (en)
ES (1) ES2281126T3 (en)
NZ (2) NZ337795A (en)
PT (1) PT970213E (en)
WO (1) WO1998041629A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies
US7803615B1 (en) 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US9133273B2 (en) 2010-11-19 2015-09-15 Eisai R&D Management Co., Ltd. Nucleic acids encoding neutralizing anti-CCL20 antibodies

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
EP1860187B1 (en) * 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012963A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
ATE443723T1 (en) * 1998-06-12 2009-10-15 Genentech Inc MONOCLONAL ANTIBODIES, CROSS-REACTIVE ANTIBODIES AND THEIR PRODUCTION PROCESSES
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU4817200A (en) * 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
JP2003507064A (en) * 1999-08-25 2003-02-25 ゲノム セラピューティックス コーポレーション Transmembrane trap for isolation of membrane-bound proteins
BR0108187A (en) * 2000-02-11 2005-04-05 Inst Genetics Llc Trade molecules and related uses
AU2048501A (en) 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
ATE415978T1 (en) 2000-07-27 2008-12-15 Genentech Inc SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2002256895B2 (en) 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CN100594935C (en) 2001-05-25 2010-03-24 人体基因组科学有限公司 Antibodies that immunospecifically bind to the TRAIL receptor
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
PT1409544E (en) 2001-07-03 2009-09-16 Genentech Inc Human dr4 antibodies and uses thereof
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
WO2003029420A2 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
EP1439225A4 (en) 2001-10-04 2005-10-26 Kansai Tech Licensing Org Co Dr5 gene promoter and siah-1 gene promoter
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP1465925A4 (en) * 2001-12-20 2006-02-08 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS
WO2003106974A2 (en) * 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
EP2500032A1 (en) 2002-06-24 2012-09-19 Genentech, Inc. APO-2 ligand/trail variants and uses thereof
BRPI0509201A (en) 2004-03-23 2007-08-28 Biogen Idec Inc receptor coupling agents and therapeutic uses of these
RU2410438C2 (en) * 2004-08-06 2011-01-27 Дженентек, Инк. Analyses and methods using biomarkers
DE602005027848D1 (en) 2004-08-06 2011-06-16 Genentech Inc TESTS AND METHODS USING BIOMARKERS
US20090175854A1 (en) * 2004-09-08 2009-07-09 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
JP2008513367A (en) * 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド Method of using death receptor ligand and CD20 antibody
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006083937A2 (en) 2005-02-02 2006-08-10 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
AU2006279618A1 (en) * 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2010042890A2 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
CA2749512A1 (en) * 2009-04-03 2010-10-07 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Antigenic determinants recognized by anti-human death receptor dr5 monoclonal antibody ad5-10, derivatives and use thereof
CA2773428A1 (en) * 2009-09-10 2011-03-17 Lonza Biologics Plc Method and system for polypeptide purification
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
NZ610153A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
WO2012117336A2 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Apoptosis-inducing molecules and uses therefor
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
PT2970473T (en) 2013-03-14 2017-10-26 Bristol Myers Squibb Co Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
ES2623260T3 (en) 2013-03-22 2017-07-10 Koninklijke Philips N.V. Device for non-invasive skin treatment using laser light
CN104693308B (en) * 2013-12-05 2020-08-04 同济大学 Smad5 protein that senses changes in intracellular pH and its application
EP3323428A1 (en) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
CN108997503B (en) * 2017-06-06 2021-07-23 深圳市中科艾深医药有限公司 Human sDR5-Fc recombinant fusion protein and application thereof in preparation of medicines for treating inflammation of reproductive system
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691A1 (en) * 1991-04-26 1992-10-28 Osaka Bioscience Institute DNA coding for human cell surface antigen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
KR100510234B1 (en) * 1995-06-29 2005-11-25 임뮤넥스 코포레이션 Cytokine that Induces Apoptosis
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
DE69836956T2 (en) 1997-03-17 2007-10-31 Human Genome Sciences, Inc. RECEPTOR 5 CONTAINING A DOMAIN RESPONSIBLE FOR CELL DEATH
EP1007562A4 (en) 1997-04-16 2000-09-27 Millennium Pharm Inc TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1860187B1 (en) * 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
JP2002508663A (en) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Apo-2DcR
AU756759B2 (en) 1997-06-26 2003-01-23 Immunex Corporation Protein that binds trail
PT1181319E (en) 1999-05-28 2009-07-14 Genentech Inc Chimeric dr4 antibodies and uses thereof
ZA200002867B (en) 1999-06-09 2001-12-07 Pfizer Prod Inc Process for preparing sertraline from chiral tetralone.
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691A1 (en) * 1991-04-26 1992-10-28 Osaka Bioscience Institute DNA coding for human cell surface antigen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHINNAIYAN A M ET AL: "SIGNAL TRANSDUCTION BY DR3, A DEATH DOMAIN-CONTAINING RECEPTOR RELATED TO TNFR-1 AND CD95", SCIENCE, vol. 274, no. 5289, 8 November 1996 (1996-11-08), pages 990 - 992, XP000676685 *
PAN G ET AL: "AN ANTAGONIST DECOY RECEPTOR AND A DEATH DOMAIN-CONTAINING RECEPTOR FOR TRAIL", SCIENCE, vol. 277, 8 August 1997 (1997-08-08), pages 815 - 818, XP002065147 *
PAN G ET AL: "THE RECEPTOR FOR THE CYTOTOXIC LIGAND TRAIL", SCIENCE, vol. 276, no. 5306, 4 April 1997 (1997-04-04), pages 111 - 113, XP000676684 *
SHERIDAN J P ET AL: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors", SCIENCE, vol. 277, 8 August 1997 (1997-08-08), pages 818 - 821, XP002075799 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6902910B2 (en) 1997-01-28 2005-06-07 Human Genome Sciences, Inc. Death domain containing receptor 4
US7803615B1 (en) 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US9017671B2 (en) 2004-10-20 2015-04-28 Genentech, Inc. Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies
US9133273B2 (en) 2010-11-19 2015-09-15 Eisai R&D Management Co., Ltd. Nucleic acids encoding neutralizing anti-CCL20 antibodies

Also Published As

Publication number Publication date
CA2285040C (en) 2009-01-27
KR20000076364A (en) 2000-12-26
JP4330180B2 (en) 2009-09-16
JP2001520513A (en) 2001-10-30
PT970213E (en) 2007-04-30
US20020098550A1 (en) 2002-07-25
CA2285040A1 (en) 1998-09-24
CN1624128A (en) 2005-06-08
JP2008081503A (en) 2008-04-10
DE69836956D1 (en) 2007-03-15
DE69836956T2 (en) 2007-10-31
EP0970213B1 (en) 2007-01-24
ATE352618T1 (en) 2007-02-15
KR100527638B1 (en) 2005-11-23
US7803615B1 (en) 2010-09-28
CN1275162A (en) 2000-11-29
NZ508381A (en) 2002-09-27
NZ337795A (en) 2001-06-29
EP0970213A2 (en) 2000-01-12
ES2281126T3 (en) 2007-09-16
CA2644454A1 (en) 1998-09-24
AU747635B2 (en) 2002-05-16
CN1184315C (en) 2005-01-12
WO1998041629A2 (en) 1998-09-24
HK1025352A1 (en) 2000-11-10
DK0970213T3 (en) 2007-05-21
AU6763598A (en) 1998-10-12

Similar Documents

Publication Publication Date Title
CA2285040A1 (en) Death domain containing receptor 5
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
AU6238698A (en) Tumor necrosis factor receptor 5
WO2000066156A8 (en) Death domain containing receptor 5
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998031806A3 (en) Fc receptors and polypeptides
WO1999035262A3 (en) Apoptosis inducing molecule ii
WO2001055308A3 (en) Nucleic acids, proteins, and antibodies
DE69841140D1 (en) INTERLEUKIN-17 RECEPTOR-SIMILAR PROTEIN
AU6847896A (en) Human endokine alpha
WO1999055868A3 (en) Fizz proteins
CA2158750A1 (en) Monoclonal antibodies to casein kinase i polypeptides
WO1996015144A3 (en) Chromosome 21 gene marker, compositions and methods using same
WO2000054651A3 (en) Human tumor necrosis factor receptor-like genes
WO2000067793A8 (en) Death domain containing receptor 4
MX9702789A (en) Novel tnf receptor death domain ligand proteins and inhibitors of ligand binding.
AU1417999A (en) Chemokine alpha-5
HK1042498A1 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6β
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2000050620A3 (en) Human endokine alpha and methods of use
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
AU5166200A (en) Human tumor necrosis factor receptor tr10
WO1998025957A3 (en) Human prt1-like subunit protein (hprt1) and human eif4g-like protein (p97) genes
WO2001005834A9 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98804537.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 337795

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008486

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2285040

Country of ref document: CA

Ref document number: 1998 540790

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997008466

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 67635/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998912966

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2285040

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1998912966

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997008466

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019997008466

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998912966

Country of ref document: EP